The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Moving well beyond the traditional approach of testing a vaccine’s collective response in large populations, this precision approach can identify how an individual’s own immune system responds to a vaccine, offering an unprecedented opportunity to measure vaccine safety and effectiveness
While continuing to offer its current breadth of genomic services, Biogazelle will become CellCarta's Center of Excellence for the development of complex genomic biomarker assays
Subscribe To Our Newsletter & Stay Updated
